Physician profile
Ashley Nottebart
NPI 1154059780
$3,929.78
in general payments reported to CMS, 2019-2025
17 companies · $1,030 in 2025
The $1,030 reported for 2025 was more than what 81% of Psychiatric/Mental Health (Nurse Practitioner) providers received nationally (typical 2025 total: $257).
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2022: $335 · 2023: $1,183 · 2024: $1,382 · 2025: $1,030.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Food and Beverage: $3,595.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Food and Beverage | $3,595.17 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Abbvie INC. | $1,088.98 | 2022-2025 | |
| Alkermes, INC. | $762.75 | 2022-2025 | Lybalvi, Aristada, Aristada Initio |
| Corium, LLC | $457.58 | 2023-2025 | Azstarys |
| Otsuka America Pharmaceutical, INC. | $335.66 | 2023-2025 | Rexulti, Abilify Asimtufii |
| Lundbeck LLC | $317.51 | 2022-2025 | Rexulti |
| Supernus Pharmaceuticals, INC. | $202.74 | 2023-2025 | Qelbree, Qelbree |
| Axsome Therapeutics, INC. | $145.73 | 2023-2024 | Auvelity |
| Takeda Pharmaceuticals U.S.A., INC. | $131.60 | 2023-2025 | Trintellix |
| Iti, INC. (D/B/A Intra-Cellular Therapies, INC.) | $101.53 | 2023-2024 | Caplyta |
| Noven Therapeutics, LLC | $93.10 | 2023-2024 | Xelstrym, Secuado |
| Ironshore Pharmaceuticals INC. | $83.74 | 2023-2024 | Jornay Pm |
| Idorsia Pharmaceuticals US INC | $61.35 | 2023-2024 | Quviviq |
| Vanda Pharmaceuticals INC. | $52.19 | 2024-2025 | Fanapt |
| Janssen Pharmaceuticals, INC | $42.54 | 2023-2025 | Spravato |
| Bausch Health US, LLC | $18.57 | 2023 | Aplenzin |
Show all 17 companies
| Company | General payments | Years | Top products |
|---|---|---|---|
| Biogen, INC. | $18.50 | 2025 | Zurzuvae |
| Collegium Pharmaceutical, INC. | $15.71 | 2025 | Jornay Pm |
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw Ashley Nottebart listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.